Leerink Partnrs Issues Optimistic Forecast for BNTC Earnings

Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) - Analysts at Leerink Partnrs upped their FY2025 EPS estimates for Benitec Biopharma in a research report issued to clients and investors on Wednesday, May 14th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings per share of ($1.18) for the year, up from their prior forecast of ($1.22). The consensus estimate for Benitec Biopharma's current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Benitec Biopharma's Q4 2025 earnings at ($0.26) EPS and FY2026 earnings at ($1.05) EPS.

Several other equities research analysts have also weighed in on the company. JMP Securities restated a "market outperform" rating and set a $20.00 price target on shares of Benitec Biopharma in a research report on Thursday. HC Wainwright restated a "buy" rating and set a $28.00 target price on shares of Benitec Biopharma in a report on Monday, March 24th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $24.71.

Benitec Biopharma Trading Up 0.7%

Shares of NASDAQ BNTC opened at $13.60 on Monday. The firm has a fifty day simple moving average of $13.68 and a two-hundred day simple moving average of $12.04. Benitec Biopharma has a 12 month low of $5.74 and a 12 month high of $16.90. The firm has a market capitalization of $348.16 million, a PE ratio of -9.01 and a beta of 0.34.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last issued its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.12.

Insiders Place Their Bets

In other news, Director Suvretta Capital Management, L bought 900,000 shares of the stock in a transaction on Wednesday, March 26th. The stock was acquired at an average cost of $13.00 per share, for a total transaction of $11,700,000.00. Following the acquisition, the director now owns 8,793,245 shares of the company's stock, valued at $114,312,185. This represents a 11.40% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Benitec Biopharma

A number of hedge funds have recently made changes to their positions in BNTC. Goldman Sachs Group Inc. purchased a new position in shares of Benitec Biopharma in the 1st quarter worth approximately $597,000. Infinitum Asset Management LLC grew its holdings in Benitec Biopharma by 435.7% in the first quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company's stock worth $14,636,000 after purchasing an additional 915,000 shares during the last quarter. AWM Investment Company Inc. grew its holdings in Benitec Biopharma by 35.2% in the first quarter. AWM Investment Company Inc. now owns 137,977 shares of the biotechnology company's stock worth $1,795,000 after purchasing an additional 35,950 shares during the last quarter. MYDA Advisors LLC increased its position in shares of Benitec Biopharma by 4.0% during the first quarter. MYDA Advisors LLC now owns 52,000 shares of the biotechnology company's stock worth $677,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Informed Momentum Co LLC purchased a new stake in shares of Benitec Biopharma during the 1st quarter valued at $512,000. 52.19% of the stock is currently owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.